159 research outputs found
Pharmaceuticals: Access, Cost, Pricing, and Directions for the Future. 13th Annual Herbert Lourie Memorial Lecture on Health Policy
Prescription drug expenditures make up less than 10 percent of total personal health care expenditures in the United States, but over the last decade the amount that Americans spend on prescription drugs has grown much faster than any other component of personal health care. For example, between 1999 and 2000, hospital care costs rose about 5 percent, physicians and clinical services 6 percent, while prescription drug expenditures climbed more than 17 percent. In dollar amounts, prescription drug expenditures doubled, from 122 billion, between 1995 and 2000. Is this an unwarranted expense that needs to be controlled, or does it represent increased value, as pharmaceuticals substitute for older, most costly treatments? What is the prevalence of health insurance coverage for prescription drugs, and how does this affect specific populations who have limited or no drug benefits? What are the components of drug prices? And what do we need to consider when we design health care policy? Stephen Soumerai and Patricia Danzon look at several aspects of pharmaceutical drug usage and pricing in the United States, illustrating their observations with their published research findings. They then briefly review recent legislative proposals to broaden public insurance coverage for prescription drugs and make their own policy recommendations.
History bias, study design, and the unfulfilled promise of pay-for-performance policies in health care
Recently, PCD published a longer, related article, “How Do You Know Which Health Care Effectiveness Research You Can Trust? A Guide for the Perplexed,” that was translational in nature. The article used simple graphs and easy-to-understand text—in five case studies—to illustrate how powerful biases, combined with weak study designs that cannot control for them, can yield untrustworthy research on several widespread interventions: influenza vaccination policy, health information technology, drug safety, prevention of childhood obesity and hospital safety (“mortality reduction”) programs. Since this was not a formal methods paper, the target audiences were policy makers, journalists, trainees, and the public. The primary goal was to understand how weak or strong study designs are likely to fail or succeed in controlling for these pervasive biases. At the start of that article, we promised to add to these case examples of common biases and research designs to show why “caution is needed in understanding and accepting the results of research that may have profound and long-lasting effects on health policy and clinical practice.” In this sixth case study, the authors revisit one of the most common and virulent biases, threats of history. Studies can mislead policymakers and clinicians because they fail to control for history, which represents pre-existing or co-occurring changes in study outcomes that were happening with or without the intervention. The policy in this case, pay-for-performance (PfP, see below), is extremely sensitive to this powerful bias because medical practice is always changing as a result of factors unrelated to a policy, such as widespread media or national guidelines supporting a life-saving treatment, e.g., beta blockers for acute MI (1). Without investigating and visualizing outcomes over time before and after a policy or intervention, it is likely that the investigators will attribute such ongoing changes to “effects” of the quality improvement policy, resulting in millions of dollars of waste implementing ineffective PfP policies worldwide
Pharmaceuticals: Access, Cost, Pricing, and Directions for the Future
Prescription drug expenditures make up less than 10 percent of total personal health care expenditures in the United States, but over the last decade the amount that Americans spend on prescription drugs has grown much faster than any other component of personal health care. For example, between 1999 and 2000, hospital care costs rose about 5 percent, physicians and clinical services 6 percent, while prescription drug expenditures climbed more than 17 percent. In dollar amounts, prescription drug expenditures doubled, from 122 billion, between 1995 and 2000. Is this an unwarranted expense that needs to be controlled, or does it represent increased value, as pharmaceuticals substitute for older, most costly treatments? What is the prevalence of health insurance coverage for prescription drugs, and how does this affect specific populations who have limited or no drug benefits? What are the components of drug prices? And what do we need to consider when we design health care policy? Stephen Soumerai and Patricia Danzon look at several aspects of pharmaceutical drug usage and pricing in the United States, illustrating their observations with their published research findings. They then briefly review recent legislative proposals to broaden public insurance coverage for prescription drugs and make their own policy recommendations
Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: controlled longitudinal study
Objective To assess the impact of direct to consumer advertising of prescription drugs in the United States on Canadian prescribing rates for three heavily marketed drugs—etanercept, mometasone, and tegaserod
Recommended from our members
Measuring access to effective care among elderly medicare enrollees in managed and fee-for-service care: a retrospective cohort study
BACKGROUND: Our aim was to compare access to effective care among elderly Medicare patients in a Staff Model and Group Model HMO and in Fee-for-Service (FFS) care. METHODS: We used a retrospective cohort study design, using claims and automated medical record data to compare achievement on quality indicators for elderly Medicare recipients. Secondary data were collected from 1) HMO data sets and 2) Medicare claims files for the time period 1994–95. All subjects were Medicare enrollees in a defined area of New England: those enrolled in two divisions of a managed care plan with different physician payment arrangements: a staff model, and a group model; and the Medicare FFS population. We abstracted information on indicators covering several domains: preventive, diagnosis-specific, and chronic disease care. RESULTS: On the indicators we created and tested, access in the single managed care plan under study was comparable to or better than FFS care in the same geographic region. Percent of Medicare recipients with breast cancer screening was 36 percentage points higher in the staff model versus FFS (95% confidence interval 34–38 percentage points). Follow up after hospitalization for myocardial infarction was 20 percentage points higher in the group model than in FFS (95% confidence interval 14–26 percentage points). CONCLUSION: According to indicators developed for use in both claims and automated medical record data, access to care for elderly Medicare beneficiaries in one large managed care organization was as good as or better than that in FFS care in the same geographic area
Health care payments in the asia pacific: validation of five survey measures of economic burden
Introduction: Many low and middle-income countries rely on out-of-pocket payments to help finance health care. These payments can pose financial hardships for households; valid measurement of this type of economic burden is therefore critical. This study examines the validity of five survey measures of economic burden caused by health care payments. Methods: We analyzed 2002/03 World Health Survey household-level data from four Asia Pacific countries to assess the construct validity of five measures of economic burden due to health care payments: any health expenditure, health expenditure amount, catastrophic health expenditure, indebtedness, and impoverishment. We used generalized linear models to assess the correlations between these measures and other constructs with which they have expected associations, such as health care need, wealth, and risk protection. Results: Measures of impoverishment and indebtedness most often correlated with health care need, wealth, and risk protection as expected. Having any health expenditure, a large health expenditure, or even a catastrophic health expenditure did not consistently predict degree of economic burden. Conclusions: Studies that examine economic burden attributable to health care payments should include measures of impoverishment and indebtedness
Recommended from our members
Barriers to self-monitoring of blood glucose among adults with diabetes in an HMO: A cross sectional study
BACKGROUND: Recent studies suggest that patients at greatest risk for diabetes complications are least likely to self-monitor blood glucose. However, these studies rely on self-reports of monitoring, an unreliable measure of actual behavior. The purpose of the current study was to examine the relationship between patient characteristics and self-monitoring in a large health maintenance organization (HMO) using test strips as objective measures of self-monitoring practice. METHODS: This cross-sectional study included 4,565 continuously enrolled adult managed care patients in eastern Massachusetts with diabetes. Any self-monitoring was defined as filling at least one prescription for self-monitoring test strips during the study period (10/1/92–9/30/93). Regular SMBG among test strip users was defined as testing an average of once per day for those using insulin and every other day for those using oral sulfonylureas only. Measures of health status, demographic data, and neighborhood socioeconomic status were obtained from automated medical records and 1990 census tract data. RESULTS: In multivariate analyses, lower neighborhood socioeconomic status, older age, fewer HbA1c tests, and fewer physician visits were associated with lower rates of self-monitoring. Obesity and fewer comorbidities were also associated with lower rates of self-monitoring among insulin-managed patients, while black race and high glycemic level (HbA1c>10) were associated with less frequent monitoring. For patients taking oral sulfonylureas, higher dose of diabetes medications was associated with initiation of self-monitoring and HbA1c lab testing was associated with more frequent testing. CONCLUSIONS: Managed care organizations may face the greatest challenges in changing the self-monitoring behavior of patients at greatest risk for poor health outcomes (i.e., the elderly, minorities, and people living in low socioeconomic status neighborhoods)
Effect of pay for performance on the management and outcomes of hypertension in the United Kingdom: interrupted time series study
Objective To assess the impact of a pay for performance incentive on quality of care and outcomes among UK patients with hypertension in primary care
Recommended from our members
Group versus individual academic detailing to improve the use of antihypertensive medications in primary care: a cluster-randomized controlled trial
Purpose To compare group versus individual academic detailing to increase diuretic or β-blocker use in hypertension. Methods We conducted a cluster-randomized controlled trial in a large health maintenance organization. Subjects (N=9820) were patients with newly treated hypertension in the year preceding the intervention (N=3692), the 9 months following the intervention (N=3556), and the second year following intervention (N=2572). We randomly allocated 3 practice sites to group detailing (N=227 prescribers), 3 to individual detailing (N=235 prescribers), and 3 to usual care (N=319 prescribers). Individual detailing entailed a physician-educator meeting individually with clinicians to address barriers to prescribing guideline-recommended medications. The group detailing intervention incorporated the same social marketing principles in small groups of clinicians. Results In the first year following the intervention, the rates of diuretic or β-blocker use increased by 13.2% in the group detailing practices, 12.5% in the individual detailing practices, and 6.2% in the usual care practices. As compared with usual care practices, diuretic or β-blocker use was more likely in group detailing practices (adjusted odds ratio (OR), 1.40; 95% confidence interval (CI), 1.11 – 1.76) and individual detailing practices (adjusted OR, 1.30; 95% CI, 0.95 – 1.79). Neither intervention affected blood pressure control. Two years following this single-visit intervention, there was still a trend suggesting a persistent effect of individual (OR, 1.22; 95% CI, 0.92 – 1.62), but not group, detailing (OR, 1.06; 95% CI, 0.80 – 1.39), as compared with usual care. Conclusion Both group and individual academic detailing improved antihypertensive prescribing over and above usual care but may require reinforcement to sustain improvements
Recommended from our members
Effect of Pediatric Behavioral Health Screening and Colocated Services on Ambulatory and Inpatient Utilization
Objective
The study sought to determine the impact of a pediatric behavioral health (BH) screening and co-location model on BH care utilization
Methods
In 2003, Cambridge Health Alliance, a Massachusetts public health system introduced BH screening and co-location of social workers within its pediatric practices in a sequential manner. An interrupted time series study of the change in trends of ambulatory, emergency and inpatient BH utilization in the 30 months following model implementation compared to the 18 months prior was conducted to determine the impact of this model on BH care utilization, Utilization data on 11,223 children ≥4 years 9 months to < 18 years 3 months seen from 2003 to 2008, contributed to the study.
Results
In the 30 months following implementation of pediatric BH screening and co-location there was a 20.4% cumulative increase in specialty BH visit rates (trend = 0.013% per month; p=0.049), and 67.7% cumulative increase in BH primary care visit rates (trend = 0.019% per month; p=0.002) compared to the expected rate predicted by the 18 month pre- intervention trend. In addition, BH emergency department visit rates increased 245% compared to the expected rate (trend = 0.01% per month; p<.001).
Conclusions
Following the implementation of a BH screening/co-location model, more children received BH treatment. Contrary to expectations, BH emergency department visits also increased. Further study is needed to determine if this is an effect of how care was organized for children newly engaged in BH care or a reflection of secular trends in BH utilization or both
- …